Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

The U.S. stock market was down for the week despite a positive Friday, as tariff developments from the Trump administration ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer continued to warn users to not trust billionaires. His ...

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...